Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.
Sign up now!
Clinical trials have defined study protocols and strict patient inclusion and exclusion criteria. As a result, outcomes of clinical trials may not always fully reflect outcomes in routine clinical practice. Registries and non-interventional studies serve many important functions including:
Several major medical registries and non-interventional studies have been launched in therapy areas in which anticoagulant therapy is used, including:
Real World Evidence and Claims Databases – a Guide for Healthcare Professionals
Prof. Craig I. Coleman gives an appreciation of the methodology used to perform Real World Evidence studies, particularly those investigating the effectiveness and safety, of non-vitamin K antagonist oral anticoagulants (or NOACs) in non-valvular atrial fibrillation patients. He also provides some key insights on what real world evidence and specifically claims databases can - and cannot - tell us. Approval number: PP-XAR-ALL-0036-2
From ROCKET AF to real-world evidence
The results of the ROCKET AF study assessing rivaroxaban compared with warfarin in patients with NVAF for the presentation of stroke are similar to non-interventional studies with rivaroxaban in the same patient population
© 2017, Bayer AG. All rights reserved. Approval number: PP-XAR-ALL-0097-2
From EINSTEIN to real-world evidence
The EINSTEIN clinical trial programme showed similar outcomes to real-world interventional study (XALIA) for the treatment of patients with VTE
© 2017, Bayer AG. All rights reserved. Approval number: PP-XAR-ALL-0092-1
XANTUS pooled: global rivaroxaban use in real-world patients with non-valvular atrial fibrillation
The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe
© 2017, Bayer AG. All rights reserved. Approval Number: PP-XAR-ALL-0639-1